info@flamel.com
Company | Technologies and Products | Investor Relations | Press Releases | Contact
 
Nicolas Flamel (1330-1418)
was a French alchemist
in the Middle Ages...
learn more

Flamel Technologies is a drug delivery company with expertise in polymer chemistry.
 
The company was founded in 1990.
 
In 1996, Flamel Technologies (FLML) became the second French biotech company to enter the Nasdaq.
 
The Company has assembled a strong team of researchers expert in polymer science and biochemistry, and owns a 50,000-square foot cGMP pharmaceutical production facility located in Pessac, France (with an annual production capacity of 2 billion tablets or capsules).
 
Flamel’s drug delivery platforms, Medusa® for therapeutic proteins and peptides, and Micropump® for small molecules , have been developed to improve the therapeutic characteristics, safety profile and ease of use of wide variety of drugs.
 
The Company is a recognized world leader in the innovation of delivery systems for small molecule and protein drugs, providing tailored solutions to the biotech and pharmaceutical industries for optimized controlled-release delivery of drugs. Flamel is turning already-marketed or new drugs into more effective and safer medicines for itself and for its partners.
 
Flamel has partnership agreements with major pharmaceutical companies.
 
The Company is actively seeking partnership agreements for the development and commercialization of products currently in its pipeline as well as for new products using Flamel’s proprietary delivery systems.

On April 25, 2008, Flamel Technologies announced the presentation of results of two week study of interferon alpha XL at the European Association for the Study of the Liver.
Click here to access the presentation entitled "Antiviral activity and tolerance of a novel interferon-alpha-2b sustained release(IFN-alpha-2bXL) compared to Peg-IFN-alpha-2b:a phase Ib trial in HCV patients".

First Quarter 2008 Earnings Announcement:
 Flamel plans to release its earnings announcement for the first quarter on May 13th after the market close.
A conference call to discuss these results is scheduled for 8:30 AM (EDT) May 14, 2008.
The dial-in number is (1) 800-374-1498 (Conference ID number: 44916095).
International callers are invited to dial-in (1) 706-634-7261.

 
Latest News Medusa ® Micropump ® Technologies

April 25, 2008
Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver

March 4, 2008
Flamel Technologies Fourth Quarter and Year End 2007 Earnings Results Conference Call,
8:30 EST

March 3, 2008
Flamel Technologies Announces Fourth Quarter and Year-End Results; Fourth quarter includes strong clinical results; new agreements; and cash maintained at $41 million

March 3, 2008
Flamel Technologies Announces Nomination of Dr. Frank Fildes to Board of Directors; Flamel Technologies also announces departure of Michel Finance and appointment of Sian Crouzet

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info
 
Micropump® and Medusa® are registered trademarks of Flamel Technologies S.A.
Copyrights © 2008 Flamel Technologies S.A. All rights reserved